These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 34712242)
1. Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors. Crowley AR; Osei-Owusu NY; Dekkers G; Gao W; Wuhrer M; Magnani DM; Reimann KA; Pincus SH; Vidarsson G; Ackerman ME Front Immunol; 2021; 12():754710. PubMed ID: 34712242 [TBL] [Abstract][Full Text] [Related]
2. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295 [TBL] [Abstract][Full Text] [Related]
3. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms. Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585 [TBL] [Abstract][Full Text] [Related]
4. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484 [TBL] [Abstract][Full Text] [Related]
5. Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques. Tolbert WD; Gohain N; Kremer PG; Hederman AP; Nguyen DN; Van V; Sherburn R; Lewis GK; Finzi A; Pollara J; Ackerman ME; Barb AW; Pazgier M Front Immunol; 2022; 13():960411. PubMed ID: 36131913 [TBL] [Abstract][Full Text] [Related]
6. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. Subedi GP; Barb AW MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264 [TBL] [Abstract][Full Text] [Related]
7. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370 [TBL] [Abstract][Full Text] [Related]
8. Role of Van Coillie J; Schulz MA; Bentlage AEH; de Haan N; Ye Z; Geerdes DM; van Esch WJE; Hafkenscheid L; Miller RL; Narimatsu Y; Vakhrushev SY; Yang Z; Vidarsson G; Clausen H Front Immunol; 2022; 13():987151. PubMed ID: 36189205 [TBL] [Abstract][Full Text] [Related]
9. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
10. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions. Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616 [TBL] [Abstract][Full Text] [Related]
11. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan. Falconer DJ; Subedi GP; Marcella AM; Barb AW ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589 [TBL] [Abstract][Full Text] [Related]
12. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936 [TBL] [Abstract][Full Text] [Related]
14. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450 [TBL] [Abstract][Full Text] [Related]
15. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414 [TBL] [Abstract][Full Text] [Related]
16. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826 [TBL] [Abstract][Full Text] [Related]
17. FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies. Freimoser-Grundschober A; Rueger P; Fingas F; Sondermann P; Herter S; Schlothauer T; Umana P; Neumann C J Chromatogr A; 2020 Jan; 1610():460554. PubMed ID: 31597603 [TBL] [Abstract][Full Text] [Related]
19. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551 [TBL] [Abstract][Full Text] [Related]
20. Functional Interactions of Common Allotypes of Rhesus Macaque FcγR2A and FcγR3A with Human and Macaque IgG Subclasses. Grunst MW; Grandea AG; Janaka SK; Hammad I; Grimes P; Karl JA; Wiseman R; O'Connor DH; Evans DT J Immunol; 2020 Dec; 205(12):3319-3332. PubMed ID: 33208458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]